WuXi Biologics (Cayman) Inc.
WXIBF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$23.29B
Close$
$-0.09
101.6% downside
Current Fair Value
101.6% downsideOvervalued by 101.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $23.29 Billion |
|---|---|
| Enterprise Value | $20.60 Billion |
| Earnings per Share | $1.19 |
| Beta | 0.6 |
| Outstanding Shares | 4,096,647,224 |
Return
| Return on Equity | 18.99% |
|---|---|
| Return on Assets | 13.96% |
| Return on Invested Capital | 23.49% |
Valuation & Multiples
| P/E Ratio | 31.13 |
|---|---|
| PEG | 989.14 |
| Price to Sales | 0.57 |
| Price to Book Ratio | 0.44 |
| Enterprise Value to Revenue | 0.48 |
| Enterprise Value to EBIT | 1.53 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
$0.07
Consensus analyst estimateRevenue Estimate
$1.69 B
Consensus analyst estimateNext Earnings Call
Expected Date
March 23, 2027
EPS Estimate
$0.11
Consensus analyst estimateRevenue Estimate
$2.09 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Wuxi Biologics (Cayman) Inc.
14,705 employees
CEO: Zhisheng Chen
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale...